Standard Biotools Inc Asset Resilience Ratio
Standard Biotools Inc asset resilience ratio. Standard Biotools Inc (LAB) has an Asset Resilience Ratio of 32.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LAB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Standard Biotools Inc (2006–2025)
Asset resilience ratio of Standard Biotools Inc from 2006 to 2025. This chart shows how Standard Biotools Inc's Asset Resilience Ratio has changed over time. Read Standard Biotools Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Standard Biotools Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Standard Biotools Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $206.69 Million | 32.95% |
| Total Liquid Assets | $206.69 Million | 32.95% |
Asset Resilience Insights
- Very High Liquidity: Standard Biotools Inc maintains exceptional liquid asset reserves at 32.95% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Standard Biotools Inc Industry Peers by Asset Resilience Ratio
Compare Standard Biotools Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Standard Biotools Inc Asset Resilience Ratio by Year (2006–2025)
Standard Biotools Inc asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Standard Biotools Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.22% | $69.36 Million | $567.75 Million | -8.38pp |
| 2024-12-31 | 20.60% | $126.15 Million | $612.34 Million | +1.04pp |
| 2023-12-31 | 19.56% | $63.19 Million | $323.07 Million | -22.92pp |
| 2022-12-31 | 42.47% | $165.78 Million | $390.31 Million | +32.14pp |
| 2021-12-31 | 10.34% | $28.45 Million | $275.21 Million | +3.96pp |
| 2020-12-31 | 6.37% | $20.70 Million | $324.76 Million | -9.50pp |
| 2019-12-31 | 15.87% | $42.02 Million | $264.81 Million | -9.72pp |
| 2018-12-31 | 25.59% | $77.72 Million | $303.65 Million | +10.63pp |
| 2017-12-31 | 14.97% | $43.01 Million | $287.35 Million | +0.13pp |
| 2016-12-31 | 14.83% | $45.45 Million | $306.39 Million | -2.92pp |
| 2015-12-31 | 17.75% | $65.86 Million | $371.06 Million | -2.27pp |
| 2014-12-31 | 20.02% | $81.59 Million | $407.56 Million | -21.96pp |
| 2013-12-31 | 41.98% | $49.08 Million | $116.92 Million | +23.20pp |
| 2012-12-31 | 18.78% | $21.36 Million | $113.73 Million | -31.53pp |
| 2011-12-31 | 50.32% | $39.91 Million | $79.33 Million | +38.84pp |
| 2007-12-31 | 11.48% | $6.29 Million | $54.78 Million | +10.11pp |
| 2006-12-31 | 1.37% | $500.00K | $36.49 Million | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more